- ACG released clinical guidelines for eosinophilic esophagitis (EoE) in Jan 2025.
- Guidelines emphasize treating inflammatory and fibrostenotic aspects, and detail changes in treatment protocols.
- PPIs are now listed as a treatment option, and dupilumab is included as a treatment option for patients 12 years and older who do not respond to PPI therapy.
- Disease activity returns when treatment stops, ongoing therapy is recommended to prevent symptom recurrence and disease progression.
- Guidelines provide recommendations for pediatric patients and underscore the importance of quality of life considerations.
- Systematic endoscopic scoring is recommended for treatment monitoring.
- Guidelines were developed using GRADE methodology with recommendations receiving strong or conditional ratings based on evidence quality.
ACG Issues First EoE Guidelines Since 2013
Conexiant
January 7, 2025
